A concise introduction to the subject under review, couched in lay terms. The molecular targets that will be modified by the proposed research should be introduced, although further explanation should be included in the Scientific rationale
section. Information on the prevalence of the disease and the social and financial implications of treatment should be included.Medical need:
This section should focus on the need for alternative/improved remedies for specific indications. For example, the limited palliative relief provided to arthritis patients by NSAIDs and the frequent impracticalities of surgery in a typically ageing population, highlight the need for genuine disease modifying therapy.Existing treatment:
This may be included as either a subsection of Medical need
, or as a separate section, discussing the short-comings of currently-available therapy and where there are significant problems, e.g., side-effects, dosing regimens, lack of efficacy, etc.Market review:
A logical sequel to the above sections and an introduction to the next is a quantification of the current market size broken down in terms of territories, for the particular indication/drug category being discussed (see sample chapter provided). An estimation of the annual growth should also be included. These data should be tabulated, both for emphasis and brevity; comments should be limited to issues likely to affect the market acceptance of, or readiness for, particular therapeutic proposals. It is important to authenticate the source of the information quoted. If possible, a table of currently available compounds (or drug types), together with their market share should be included. The Editor may be able to obtain some data on a case-by-case basis.Current research goals:
This section should summarise briefly the aims of current research into the therapeutic area or drug class in question, as a prelude to the next section.
Scientific rationale: Please describe clearly any complex scientific concepts, so that readers are able to understand the basic principles of the specific disease target and thereby decide whether the proposal is scientifically tenable. The scientific hypothesis can form the basis for the prediction or anticipation of adverse events to which attention should be drawn. Including an illustration to aid understanding is recommended.Competitive environment:
This section should review specific compounds with claims for activity in the therapeutic target involved. The products selected would normally be derived from the literature or Pharmaprojects, although other substantiated sources may be accessed. The aim of this section is to demonstrate clearly and succinctly what compounds are in development for a given indication, by whom they are being developed and what stage they have reached in development. Authors should provide their comments in the form of evaluated and considered opinions on the prospects for this particular drug. Any additional data should be included here, e.g., potency, side-effects, likely success, etc.
Each review should include a table following the template provided below. Authors will be provided with information from Pharmaprojects to complete this section.Potential development issues:
These may arise as a consequence of the reviews above (e.g., class-specific, pharmacologically-linked adverse events) or be consequential of particular chemical structures. Alternatively, social issues and those of high public interest or comparatively elusive patient populations may influence the attractiveness of a given area. Existing orphan drug studies should be indicated where appropriate.Conclusion:
The conclusion for all articles should contain a brief summary of the data presented in the article. Please note that this section is meant to be distinct from, and to appear before the ‘Expert opinion’ section.